|
Sign In to gain access to subscriptions and/or personal tools.
|
Preclinical Restenosis Models: Challenges and Successes
Arturo G. Touchard
Robert S. Schwartz
Minneapolis Heart Institute, Minneapolis, Minnesota 55407, USA
Correspondence: Address correspondence to: Robert S. Schwartz, Minneapolis Heart Institute, Minnesota Cardiovascular Research Institute, 928 E. 28th St., Minneapolis, MN 55407, USA; e-mail:rss{at}rsschwartz.com
Coronary artery disease remains a major problem for Western societies. The advent of percutaneous interventions, including stents has brought clinical care to a new level of efficacy, yet problems remain. Restenosis following stenting in human coronary arteries appears at last to be yielding to therapeutic strategies, especially drug eluting stents. Because therapeutic percutaneous coronary intervention is widely dominated by the intracoronary stent, restenosis therapies must include the stented coronary artery. Animal models and in particular the porcine coronary model seem to represent the human coronary artery reaction to stenting. It mimics several clinical conditions including thrombosis and neointimal formation. A key question in the era of intravascular technologies is how well this and other models can predict clinical events. This paper discusses the models and their application.
Key Words: Neointima restenosis stent vascular injury
Toxicologic Pathology, Vol. 34, No. 1,
11-18 (2006)
DOI: 10.1080/01926230500499407

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. E. Leigh Perkins
Preclinical Models of Restenosis and Their Application in the Evaluation of Drug-Eluting Stent Systems
Veterinary Pathology,
January 1, 2010;
47(1):
58 - 76.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. George
A new model of murine in situ stenting: great things come in small packages
Cardiovasc Res,
January 1, 2010;
85(1):
5 - 6.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Chamberlain, M. Wheatcroft, N. Arnold, H. Lupton, D. C. Crossman, J. Gunn, and S. Francis
A novel mouse model of in situ stenting
Cardiovasc Res,
January 1, 2010;
85(1):
38 - 44.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Tharp, I. Masseau, J. Ivey, V. K. Ganjam, and D. K. Bowles
Endogenous testosterone attenuates neointima formation after moderate coronary balloon injury in male swine
Cardiovasc Res,
April 1, 2009;
82(1):
152 - 160.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Schwartz, E. Edelman, R. Virmani, A. Carter, J. F. Granada, G. L. Kaluza, N. A.F. Chronos, K. A. Robinson, R. Waksman, J. Weinberger, et al.
Drug-Eluting Stents in Preclinical Studies: Updated Consensus Recommendations for Preclinical Evaluation
Circ Cardiovasc Interv,
October 1, 2008;
1(2):
143 - 153.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D.L. Tharp, B.R. Wamhoff, H. Wulff, G. Raman, A. Cheong, and D.K. Bowles
Local Delivery of the KCa3.1 Blocker, TRAM-34, Prevents Acute Angioplasty-Induced Coronary Smooth Muscle Phenotypic Modulation and Limits Stenosis
Arterioscler Thromb Vasc Biol,
June 1, 2008;
28(6):
1084 - 1089.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|